# If You Invested in Greater Cannabis (GCAN) > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/if-you-invested-in-greater-cannabis-gcan/ > **Published:** 2026-07-05T12:32:19-04:00 | **Last Modified / Clinically Audited:** 2026-09-09T10:04:57-04:00 > **Clinical Summary:** How to evaluate cannabis clinical trials and distinguish rigorous research from market hype. Clinical guidance on cannabis-based pharmaceutical development. --- ✦ New CED Clinical Relevance#45 Clinical ContextBackground information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. ResearchCancerCBDPainAnxietySafetyPolicy Dr. Caplan’s Take“I appreciate when cannabis companies pursue rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), but we need to be clear about where we stand: most [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) remain in early development stages, and until we see peer-reviewed data from completed human trials published in medical journals, I counsel patients to view these efforts as promising research rather than proven therapies.” Clinical Perspective 🔬 As cannabis companies increasingly invest in [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) pathways, healthcare providers should recognize that rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and FDA oversight differ substantially from the unregulated cannabis products currently available in most dispensaries. While company-sponsored research may eventually yield cannabinoid-based pharmaceuticals with established efficacy and safety profiles—similar to dronabinol or nabiximols already approved for specific indications—the timeline for such development is lengthy and uncertain. Clinicians should remain cautious about extrapolating promising early-stage research to current patient recommendations, as commercial interests may accelerate marketing claims ahead of robust evidence. In practice, this means maintaining clear distinctions in patient conversations between investigational cannabis-derived compounds under development, FDA-approved cannabinoid medications, and the diverse, unregulated products patients may access locally, while continuing to counsel patients based on the current evidence base rather than speculative future therapies. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20If%20You%20Invested%20in%20Greater%20Cannabis%20%28GCAN%29%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68306)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68306)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20If%20You%20Invested%20in%20Greater%20Cannabis%20%28GCAN%29%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68306)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.stocktitan.net/tools/stock-return-calculator/GCAN](https://www.stocktitan.net/tools/stock-return-calculator/GCAN) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).